Entero Therapeutics (ENTO) Stock Price, News & Analysis

Company Overview

Entero Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of targeted and orally delivered therapies for the treatment of patients with gastrointestinal diseases. The company's pipeline candidates include latiglutenase, a targeted oral biotherapeutic for celiac disease designed to breakdown gluten into non-immunogenic peptides, currently under Phase 2 studies; and capeserod, a selective 5-HT4 receptor partial agonist under Phase 1 studies for the treatment of gastroparesis. It is also involved in the development of adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients, currently under Phase 2 studies for the treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis and chronic pancreatitis; and niclosamide, an oral small molecule with anti-inflammatory inhibitor therapy, currently under Phase 2 studies for the treatment of ulcerative proctitis and ulcerative proctosigmoiditis, as well as immune checkpoint inhibitor-associated colitis and diarrhea in metastatic cancer patients. The company was formerly known as First Wave BioPharma, Inc. and changed its name to Entero Therapeutics, Inc. in May 2024. Entero Therapeutics, Inc. was incorporated in 2014 and is based in Boca Raton, Florida.

Key Stats

• Today's Range: $0.45 to $0.57
• 50-Day Range: $0.34 to $0.59
• 52-Week Range: $0.19 to $1.93
• Volume: 1.77 million shs
• Average Volume: 727,922 shs
• Market Capitalization: $2.53 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

ENTO Stock Analysis - Frequently Asked Questions

How have ENTO shares performed this year?

Entero Therapeutics' stock was trading at $0.6220 at the beginning of the year. Since then, ENTO stock has decreased by 14.6% and is now trading at $0.5310.
View the best growth stocks for 2025 here.

How were Entero Therapeutics' earnings last quarter?

Entero Therapeutics, Inc. (NASDAQ:ENTO) announced its earnings results on Thursday, May, 15th. The company reported ($0.21) earnings per share (EPS) for the quarter.

How do I buy shares of Entero Therapeutics?

Shares of ENTO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Entero Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Entero Therapeutics investors own include Conduit Pharmaceuticals (CDT), BIOLASE (BIOL), Cyclacel Pharmaceuticals (CYCC), Dare Bioscience (DARE), PMGC (ELAB), TRACON Pharmaceuticals (TCON) and Tempest Therapeutics (TPST).

Company Calendar

• Last Earnings: 5/15/2025
• Today: 6/22/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ENTO
• Previous Symbol: NASDAQ:ENTO
• CIK: 1604191
• Web: www.enterothera.com
• Phone: 561-589-7020
• Fax: N/A
• Employees: 9
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$18.06 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -1,063.82%
• Return on Assets: -26.06%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.90
• Quick Ratio: 2.90

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.82) per share
• Price / Book: -0.65

Miscellaneous

• Outstanding Shares: 4,770,000
• Free Float: 4,730,000
• Market Cap: $2.53 million
• Optionable: N/A
• Beta: 0.85